標的型タンパク質分解における分子接着剤とPROTAC:メカニズム,進歩,治療の可能性
1Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Biochemical pharmacology
|September 4, 2025
まとめ
標的型タンパク質分解 (TPD) は 病気を引き起こすタンパク質を排除するために 体のシステムを利用します 分子接着剤とPROTACは2つのTPD方法であり,新しい治療の可能性を提供します.
科学分野:
- 生物化学
- 分子生物学
- 薬理学について
背景:
- 標的型タンパク質分解 (TPD) は新しい治療戦略を提供します.
- 特定のタンパク質を 選択的に除去します 伝統的な抑制剤とは違います
- TPDは,以前は難解なタンパク質を含む,薬剤可能な標的の範囲を拡大します.
研究 の 目的:
- 分子粘着剤とPROTACの比較的な概要を提示する.
- そのメカニズム,設計原理,治療応用について議論する.
- TPDの最近の進歩と臨床的進歩を強調する.
主な方法:
- 分子粘着剤とPROTACの比較分析
- メカニズム,設計,物理化学的性質のレビュー
- 臨床的進歩とケーススタディの検討
主要な成果:
- 分子粘着剤とPROTACは,異なるTPD戦略を表しています.
- 両方とも薬効性プロテオームを 拡張したものです
- 最近の進歩により 新しい分解剤の発見が加速しています
結論:
- TPDは分子接着剤と PROTAC を使って 薬の発見を形づくっています
- これらのアプローチは様々な病気の治療に 重要な可能性を秘めています
- 進行中の研究と臨床試験が 治療の革新を促しています
関連する概念動画
Regulated Protein Degradation
2.6K
2.6K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tagging and Fusion Proteins
6.9K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.9K
The Proteasome
1.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.1K
Protein Networks
4.1K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.1K
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K


